Exhibit 99.1

MediCor Ltd. Announces Acquisition of Laboratoires Eurosilicone S.A.

    LAS VEGAS--(BUSINESS WIRE)--May 19, 2004--Las Vegas-based MediCor
Ltd. (OTCBB: MDCR) announced today that it has signed a definitive
agreement to acquire Laboratoires Eurosilicone S.A., the third largest
manufacturer of breast implants in the world.
    Eurosilicone is a privately owned company located in Apt, France,
with sales of medical devices worldwide. The closing of the
acquisition is subject to concluding MediCor's financing and other
customary conditions.
    Eurosilicone currently distributes its products in approximately
70 countries throughout Europe, Asia, South America and Africa and has
17 percent of the breast implant market outside the United States. The
company employs approximately 155 people in its two ISO-certified
manufacturing facilities, both of which have additional production
capacity, thus enhancing MediCor's ability to meet increased product
demand and support new product introductions.
    Eurosilicone develops, manufactures and markets a full range of
silicone implants for the aesthetic, plastic and reconstructive
surgery markets, including silicone gel and saline-filled breast
implants, with both round and anatomical shapes and smooth or unique
micro textured surfaces. Eurosilicone also markets a line of external
breast prostheses under the Maxima brand sold by its Europrotex
division, available in six different shapes and a wide range of sizes.
Eurosilicone also manufactures and markets a range of other silicone
implants, including tissue expanders, testicular implants, gluteus
implants, calf implants, nasal implants, malar implants and chin
implants.
    According to Theodore R. Maloney, MediCor Chief Executive Officer,
"The acquisition of Eurosilicone, combined with our existing breast
implant product pipeline, will immediately position MediCor as the
third leading manufacturer and distributor of breast implants
worldwide, behind Inamed Corp. (NASDAQ: IMDC) and Mentor Corp. (NYSE:
MNT). This acquisition continues the execution of our long-term
strategies of assembling the most experienced management team,
acquiring businesses in the existing global aesthetic, plastic and
reconstructive and dermatology markets, and then leveraging that
position through enhanced marketing programs. We're proud to team up
in this effort with the Eurosilicone team, led by the Tourniaire
family, which has committed itself to quality, innovation and service,
hallmarks of our business strategy."
    MediCor plans on retaining Eurosilicone's current employee base
and expanding its operations, which are located in the south of
France. Additionally, the founder and current executive management
team will continue to be critical and vibrant parts of Eurosilicone's
future. In particular, Francois M. Tourniaire has agreed to continue
in the position of President Directeur Generale. Maloney added that
MediCor also places a high value on the breadth and strength of
Eurosilicone's existing third-party distributors worldwide and looks
forward to retaining and building upon those relationships.
    MediCor was founded by Chairman of the Board Donald K. McGhan, the
founder and former Chairman and Chief Executive Officer of Inamed.
Other members of MediCor's management team include former Inamed Chief
Operating Officer Jim J. McGhan, who now serves as MediCor's COO;
former President of McGhan Medical Corp. (now Inamed Aesthetics), C.
Scott Eschbach, Ph.D., who serves as CEO of MediCor Development Corp.;
and former Inamed Executive Vice President of Sales and Marketing
David G. Barella, who now serves as MediCor's Executive Vice President
of international marketing and sales.
    MediCor acquires, develops, manufactures and markets products for
medical specialties in aesthetic, plastic and reconstructive surgery
and dermatology markets. Products include surgically implantable
prostheses for aesthetic, plastic and reconstructive surgery and scar
management products. Its products are sold worldwide to hospitals,
surgery centers and physicians through various distributors and direct
sales personnel. MediCor's strategy is to be the leading integrator of
selected international medical device markets, technologies and
corporations. To achieve this strategy, MediCor intends to build upon
and expand its business lines, primarily in the aesthetic, plastic and
reconstructive surgery and dermatology markets. MediCor intends to
accomplish this growth through the expansion of existing product lines
and offerings and through the acquisition of companies and other
assets, including intellectual property rights or distribution rights.

    This release may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements are based upon the current beliefs and expectations of
MediCor's management and are subject to significant risks and
uncertainties. Actual results may differ from those set forth in the
forward-looking statements.
    The following factors, among others, could cause actual results to
differ from those set forth in the forward-looking statements: the
ability to obtain requisite financing, the risk of instability in the
capital markets in the U.S. and internationally, the ability to obtain
governmental approvals of the transactions; the ability to satisfy any
agreed closing conditions; the risk that the businesses will not be
integrated successfully; the risk that cost savings from acquisition
transactions may not be realized or may take longer to realize than
expected; disruption from transactions making it more difficult to
maintain relationships with customers, employees or suppliers;
increased competition and its effect on pricing, spending, third-party
relationships and revenues; the outcome of certain political and legal
proceedings; and the risk of new and changing regulations in the
United States and internationally. Additional factors that could cause
MediCor's results to differ materially from those described in the
forward-looking statements can be found in the 2003 Annual Report on
Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB of
MediCor filed with the Securities and Exchange Commission and
available at the Securities and Exchange Commission's Internet site
(http://www.sec.gov).

    CONTACT: MediCor Ltd., Las Vegas
             Marc S. Sperberg, 702-932-4560